

Global Tumor-specific Antigen Market

<https://marketpublishers.com/r/G4F786BD175EN.html>

Date: May 2019

Pages: 140

Price: US\$ 2,750.00 (Single User License)

ID: G4F786BD175EN

Abstracts

Report Scope:

The scope of this report is broad and covers category, source and applications of Tumor-specific Antigen. The market has been segmented by source into coding region and Non-Coding region. Revenue forecasts from 2017 to 2023 are given for each segment and regional market with estimated value derived from the revenue of manufacturers.

The report also includes a discussion of the major players across each region of the Tumor-specific antigen market. Further, it explains the major drivers and regional dynamics of the global Tumor-specific antigen market and current trends within the industry.

The report concludes with a special focus on vendor landscape and includes detailed profiles of the main vendors in the Tumor-specific antigen market.

Report Includes:

75 data tables and 61 additional tables

An overview of the global market for tumor-specific antigen

Analyses of global market trends, with data from 2017, 2018, and projections of compound annual growth rates (CAGRs) through 2023

Coverage of various types of product available in the tumor-specific antigen market and discussion of their potential applications

Information on oncofetal, oncoviral, overexpressed/accumulated, mutated,

lineage restricted and idiotypic tumor-specific antigens and discussion of their specific targets

Insights into regulatory framework and policies and funding initiatives by the government for cancer research

A look into advancements in antigen specific T-Cell therapy for cancer and innovation within the industry

Detailed profiles of the major vendors in the global tumor-specific antigen market including Agilent Technologies Inc., AIVITA Biomedical, Eli Lilly and Co., GO Therapeutics and Merck Millipore

Contents

CHAPTER 1 INTRODUCTION

Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports

CHAPTER 2 SUMMARY AND HIGHLIGHTS

CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND

Market Overview
Market Potential
Investment Analysis
Regulatory Framework
United States
European Union
Australia
Japan
India
China
Industry Growth Drivers
Surging Demand for Potential Cancer Biomarker Candidates
Rising Prevalence of Cancer
Increasing Investments in Cancer Diagnosis and Research
Rising Focus on Developing Targeted Therapies
Antigen Specific T-Cell Therapy

CHAPTER 4 TUMOR-SPECIFIC ANTIGEN MARKET BY CATEGORY

Oncofetal
Oncoviral

Overexpressed/Accumulated
CT9/CT10
Mutated
Lineage-Restricted Antigen
Idiotypic
Others

CHAPTER 5 TUMOR-SPECIFIC ANTIGEN MARKET BY SOURCE

Coding Region
Non-Coding Region
Growing the Background of Immunotherapy Targets

CHAPTER 6 TUMOR-SPECIFIC ANTIGEN MARKET BY APPLICATION

Diagnostics
Drug Discovery and Development
Therapeutics
Risk Assessment
Prognostics
Clinical and Basic Research

CHAPTER 7 TUMOR-SPECIFIC ANTIGEN MARKET BY REGION

North America
United States
Canada
Europe
United Kingdom
France
Germany
Spain
Rest of Europe
Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific

Rest of the World

Latin America

Middle East and Africa

CHAPTER 8 TUMOR-SPECIFIC ANTIGEN MARKET INDUSTRY STRUCTURE

Industry Structure

Procurement of Raw Materials

Manufacturing/Development Process

End-Users

Innovation in the Market

Competitive Analysis

CHAPTER 9 COMPANY PROFILES

ABCAM PLC

AGILENT TECHNOLOGIES INC.

AIVITA BIOMEDICAL

BBI GROUP

BIOM?RIEUX SA

BIO-RAD LABORATORIES INC.

BRIGHTPATH BIOTHERAPEUTICS

CARIS LIFE SCIENCES INC.

CISBIO BIOASSAYS

CREATIVE DIAGNOSTICS

ELI LILLY AND CO.

ENZO BIOCHEM INC.

EXTERNAUTICS

F. HOFFMANN-LA ROCHE LTD.

GO THERAPEUTICS

JANSSEN GLOBAL SERVICES LLC

LEE BIOSOLUTIONS INC.

MERCK MILLIPORE

MESO SCALE DIAGNOSTICS, LLC

PERKINELMER INC.

QUEST DIAGNOSTICS

SIGNOSIS INC.

List Of Tables

LIST OF TABLES

Summary Table: Global Market for Tumor-specific Antigen, by Source, Through 2023

Table 1: Investment Analysis

Table 2: Biomarkers for Cancer Detection, Diagnosis and Prognosis

Table 3: Protein Arrays: Cancer Biomarker Discovery

Table 4: Global Prevalence of Cancer, by Type, 2016

Table 5: Regional Cancer Prevalence, by Type, 2015 and 2016

Table 6: Investment in Cancer, by Area of Research, 2017

Table 7: Investments in Cancer-Based Research, 2016-2018

Table 8: Molecular Targeted Therapy in Anticancer

Table 9: CAR Target Antigen for Hematologic Malignancies and Potential Off-Tumor Targets

Table 10: Global Market for Tumor-specific Antigen, by Category, Through 2023

Table 11: Tumor Antigen

Table 12: Global Market for Oncofetal Antigen, by Region, Through 2023

Table 13: Pharmaceutical and Bioinformatic Partnerships and Alliances

Table 14: Global Market for Oncoviral Antigen, by Region, Through 2023

Table 15: U.S. R&D Funding for Basic Research

Table 16: Global Market for Overexpressed/Accumulated Antigen, by Region, Through 2023

Table 17: Investment in Cancer, by Research Area

Table 18: Global Market for CT9/CT10 Antigen, by Region, Through 2023

Table 19: Regional Cancer Prevalence, by Type, 2015 and 2016

Table 20: Global Market for Mutated Antigen, by Region, Through 2023

Table 21: Global Leukemia Deaths, 2016

Table 22: Estimated New Cases of Leukemia, Lymphoma and Myeloma in the U.S., 2018

Table 23: Global Market for Lineage Restricted Antigen, by Region, Through 2023

Table 24: Global Cancer Prevalence and Mortality Rate, 2012 and 2030

Table 25: Global Prevalence of Cancer, by Type, 2016

Table 26: Global Cancer Mortalities, by Type, 2016

Table 27: Global Market for Idiotypic-Based Antigen, by Region, Through 2023

Table 28: Clinical Trials in Idiotypic

Table 29: Identified Post-Translationally Modified AutoAntigen

Table 30: Global Market for Other Antigen, by Region, Through 2023

Table 31: Global Prevalence of Diabetes, 2017 and 2045

- Table 32: Global Market for Tumor-specific Antigen, by Source, Through 2023
- Table 33: Tumor and Tissue-Specific Promoters Used to Generate Tumor-specific Antigen Sourced Through Coding Region
- Table 34: Global Market for Coding Region-Based Antigen, by Region, Through 2023
- Table 35: Global Market for Non-Coding Region-Based Antigen, by Region, Through 2023
- Table 36: Global Market for Tumor-specific Antigen, by Application, Through 2023
- Table 37: Key Immunological Techniques for Diagnosis of Cancer
- Table 38: Global Market for Tumor-specific Antigen in Diagnostic Applications, by Region, Through 2023
- Table 39: Circulating Antigen and Immunodiagnosis of Cancer
- Table 40: Global Market for Tumor-specific Antigen in Drug Discovery and Development Applications, by Region, Through 2023
- Table 41: Clinical Trials Involving Tumor-specific Antigen for Cancer Therapeutics
- Table 42: Global Market for Tumor-specific Antigen in Therapeutic Applications, by Region, Through 2023
- Table 43: Global Market for Tumor-specific Antigen in Risk Assessment Applications, by Region, Through 2023
- Table 44: Global Market for Tumor-specific Antigen in Prognostic Applications, by Region, Through 2023
- Table 45: Global Prevalence of Different Cancers, by Country, 2016
- Table 46: Deaths from Different Cancer Type, by Country, 2016
- Table 47: NCI Funding, 2012-2017
- Table 48: Global Market for Tumor-specific Antigen in Clinical and Basic Research Applications, by Region, Through 2023
- Table 49: North American Market for Tumor-specific Antigen, by Country, Through 2023
- Table 50: North American Market for Tumor-specific Antigen, by Category, Through 2023
- Table 51: U.S. Funding for Cancer Research, by Type, 2015 and 2016
- Table 52: North American Market for Tumor-specific Antigen, by Source, Through 2023
- Table 53: U.S. Market for Tumor-specific Antigen, by Source, Through 2023
- Table 54: Canadian Market for Tumor-specific Antigen, by Source, Through 2023
- Table 55: North American Market for Tumor-specific Antigen, by Application, Through 2023
- Table 56: European Market for Tumor-specific Antigen, by Country/Region, Through 2023
- Table 57: European Market for Tumor-specific Antigen, by Category, Through 2023
- Table 58: Cancer Prevalence in the U.K., by Country, 2015 and 2020
- Table 59: European Market for Tumor-specific Antigen, by Source, Through 2023

- Table 60: U.K. Market for Tumor-specific Antigen, by Source, Through 2023
- Table 61: Funding for Biology and Basic Sciences for Cancer Research in France, 2007-2015
- Table 62: French Market for Tumor-specific Antigen, by Source, Through 2023
- Table 63: German Market for Tumor-specific Antigen, by Source, Through 2023
- Table 64: Ongoing Cancer-Based Trials in Germany
- Table 65: Cancer Cases in Spain, 2012 and 2015
- Table 66: European Market for Tumor-specific Antigen, by Application, Through 2023
- Table 67: Spanish Market for Tumor-specific Antigen, by Source, Through 2023
- Table 68: Projects Recommended to the NCU Board for Funding, 2016
- Table 69: Rest of European Market for Tumor-specific Antigen, by Source, Through 2023
- Table 70: Asia-Pacific Market for Tumor-specific Antigen, by Country/Region, Through 2023
- Table 71: Asia-Pacific Market for Tumor-specific Antigen, by Source, Through 2023
- Table 72: Cancer Incidence in China, 2016
- Table 73: Asia-Pacific Market for Tumor-specific Antigen, by Category, Through 2023
- Table 74: Chinese Market for Tumor-specific Antigen, by Source, Through 2023
- Table 75: Clinical Trials for Cancer
- Table 76: Indian Market for Tumor-specific Antigen, by Source, Through 2023
- Table 77: Asia-Pacific Market for Tumor-specific Antigen, by Application, Through 2023
- Table 78: Japanese Market for Tumor-specific Antigen, by Source, Through 2023
- Table 79: Australian Market for Tumor-specific Antigen, by Source, Through 2023
- Table 80: Change in Cancer Prevalence in Other APAC Countries, 2005-2016
- Table 81: Rest of APAC Market for Tumor-specific Antigen, by Source, Through 2023
- Table 82: Clinical Trials for Tumor-specific Antigen: Singapore
- Table 83: RoW Market for Tumor-specific Antigen, by Region, Through 2023
- Table 84: Cancer Incidence in Brazil, 2016
- Table 85: Latin American Market for Tumor-specific Antigen, by Source, Through 2023
- Table 86: RoW Market for Tumor-specific Antigen, by Category, Through 2023
- Table 87: Causes of Death in Argentina and Percentage Change, 2005-2016
- Table 88: RoW Market for Tumor-specific Antigen, by Source, Through 2023
- Table 89: RoW Market for Tumor-specific Antigen, by Application, Through 2023
- Table 90: Cancer Prevalence in Kenya, by Type, 2015 and 2016
- Table 91: Middle Eastern and African Market for Tumor-specific Antigen, by Source, Through 2023
- Table 92: Global Suppliers of Tumor-specific Antigen Market
- Table 93: Selected Tumor-specific Antigen Companies
- Table 94: Cancer Antigen for Clinical Trials, as of January 2019

Table 95: Product Launches, Product Development and FDA Clearance

Table 96: Notable Mergers and Acquisitions

Table 97: Notable Agreements, Collaborations and Partnerships

Table 98: Notable Funding, Expansion and Divestment

Table 99: Abcam PLC: Product Portfolio

Table 100: Abcam PLC: Recent Developments

Table 101: Agilent Technologies Inc.: Product Portfolio

Table 102: Agilent Technologies Inc.: Recent Developments

Table 103: AIVITA Biomedical: Product Portfolio

Table 104: AIVITA Biomedical: Recent Developments

Table 105: BBI Group: Product Portfolio

Table 106: Biom?rieux SA: Product Portfolio

Table 107: Bio-Rad Laboratories Inc.: Product Portfolio

Table 108: Bio-Rad Laboratories Inc.: Recent Developments

Table 109: BrightPath Biotherapeutics: Product Portfolio

Table 110: BrightPath Biotherapeutics: Recent Developments

Table 111: Caris Life Sciences Inc.: Product Portfolio

Table 112: Caris Life Sciences Inc.: Recent Developments

Table 113: Cisbio Bioassays: Product Portfolio

Table 114: Creative Diagnostics: Product Portfolio

Table 115: Creative Diagnostics: Recent Developments

Table 116: Eli Lilly and Co.: Product Portfolio

Table 117: Eli Lilly and Co.: Recent Developments

Table 118: Enzo Biochem Inc.: Product Portfolio

Table 119: Enzo Biochem Inc.: Recent Developments

Table 120: Externautics: Product Portfolio

Table 121: F. Hoffmann-La Roche Ltd.: Product Portfolio

Table 122: F. Hoffmann-La Roche Ltd.: Recent Developments

Table 123: GO Therapeutics: Product Portfolio

Table 124: GO Therapeutics: Recent Developments

Table 125: Janssen Global Services LLC: Product Portfolio

Table 126: Janssen Global Services LLC: Recent Developments

Table 127: Lee Biosolutions Inc.: Product Portfolio

Table 128: Merck Millipore: Product Portfolio

Table 129: Merck Millipore: Recent Developments

Table 130: Meso Scale Diagnostics, LLC: Product Portfolio

Table 131: Meso Scale Diagnostics, LLC: Recent Developments

Table 132: PerkinElmer Inc.: Product Portfolio

Table 133: PerkinElmer Inc.: Recent Developments

Table 134: Quest Diagnostics: Product Portfolio

Table 135: Quest Diagnostics: Recent Developments

Table 136: Signosis Inc.: Product Portfolio

List Of Figures

LIST OF FIGURES

- Summary Figure: Global Market for Tumor-specific Antigen, by Source, 2017-2023
- Figure 1: Regional Prevalence of Cancer, 2015-2016
- Figure 2: Global Prevalence of Cancer, by Type, 2016
- Figure 3: Targeting of Tumor-specific Mutated Antigen in T-Cell Immunotherapy
- Figure 4: Global Leukemia Deaths, 2016
- Figure 5: Estimated New Cases of Leukemia, Lymphoma and Myeloma in the U.S., 2018
- Figure 6: Global Cancer Prevalence and Mortality Rate, 2012 and 2030
- Figure 7: Global Prevalence of Cancer, by Type, 2016
- Figure 8: Global Cancer Mortalities, by Type, 2016
- Figure 9: Determination of Antibody Idiotype
- Figure 10: Global Prevalence of Diabetes, 2017 and 2045
- Figure 11: Sources of Tumor-specific Antigen
- Figure 12: Key Applications: Tumor-specific Antigen
- Figure 13: Drug Discovery Cycle
- Figure 14: Clinical Cancer Research for Therapeutic Applications
- Figure 15: The Role of Prognostic and Predictive Markers in Individualized Treatment
- Figure 16: Global Prevalence of Different Cancers, by Country, 2016
- Figure 17: Deaths from Different Cancer Type, by Country, 2016
- Figure 18: NCI Funding, 2012-2017
- Figure 19: Funding for Biology and Basic Sciences for Cancer Research in France, 2007-2015
- Figure 20: Cancer Incidence in China, 2016
- Figure 21: Major Breakthroughs in Cancer Research: India
- Figure 22: Cancer Prevalence in Kenya, by Type, 2015 and 2016
- Figure 23: Tumor-specific Antigen Industry Structure
- Figure 24: Tumor-specific Antigen Development Flow Chart

I would like to order

Product name: Global Tumor-specific Antigen Market

Product link: <https://marketpublishers.com/r/G4F786BD175EN.html>

Price: US\$ 2,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G4F786BD175EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970